CN108114083A - A kind of Chinese medicine composition for preventing hepatic injury - Google Patents
A kind of Chinese medicine composition for preventing hepatic injury Download PDFInfo
- Publication number
- CN108114083A CN108114083A CN201711347613.2A CN201711347613A CN108114083A CN 108114083 A CN108114083 A CN 108114083A CN 201711347613 A CN201711347613 A CN 201711347613A CN 108114083 A CN108114083 A CN 108114083A
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- liver
- chinese medicine
- dry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 231100000753 hepatic injury Toxicity 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 239000000284 extract Substances 0.000 claims abstract description 67
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 24
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 21
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 21
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 20
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 19
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 19
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 16
- 240000006365 Vitis vinifera Species 0.000 claims abstract description 14
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 235000019441 ethanol Nutrition 0.000 claims description 21
- 206010067125 Liver injury Diseases 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 8
- 240000006079 Schisandra chinensis Species 0.000 claims description 7
- 244000241872 Lycium chinense Species 0.000 claims description 5
- 235000015468 Lycium chinense Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 235000019640 taste Nutrition 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 1
- 241000736075 Schisandra Species 0.000 abstract description 9
- 210000004185 liver Anatomy 0.000 description 40
- 238000012360 testing method Methods 0.000 description 37
- 241001465754 Metazoa Species 0.000 description 28
- 241000700159 Rattus Species 0.000 description 23
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 23
- 239000000463 material Substances 0.000 description 23
- 239000012153 distilled water Substances 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 230000001476 alcoholic effect Effects 0.000 description 12
- 239000013642 negative control Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 229960003180 glutathione Drugs 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 210000005229 liver cell Anatomy 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 230000034994 death Effects 0.000 description 8
- 238000003305 oral gavage Methods 0.000 description 7
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 208000005374 Poisoning Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 231100000572 poisoning Toxicity 0.000 description 5
- 230000000607 poisoning effect Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 231100000460 acute oral toxicity Toxicity 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000003859 lipid peroxidation Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000036244 malformation Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- CFRFHWQYWJMEJN-UHFFFAOYSA-N 9h-fluoren-2-amine Chemical class C1=CC=C2C3=CC=C(N)C=C3CC2=C1 CFRFHWQYWJMEJN-UHFFFAOYSA-N 0.000 description 3
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 208000010796 X-linked adrenoleukodystrophy Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 description 3
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- -1 oxygen Free radical Chemical class 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- RIXNFYQZWDGQAE-DFHVBEEKSA-N (4as,6ar,6as,6br,8ar,10s,12ar,14bs)-10-acetyloxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C([C@H]1C2=CC[C@H]34)C(C)(C)CC[C@]1(C(O)=O)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)C)C1(C)C RIXNFYQZWDGQAE-DFHVBEEKSA-N 0.000 description 2
- 150000004359 1,8-dihydroxyanthraquinones Chemical class 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241001269238 Data Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 235000014666 liquid concentrate Nutrition 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- YHQDZJICGQWFHK-UHFFFAOYSA-N 4-nitroquinoline N-oxide Chemical class C1=CC=C2C([N+](=O)[O-])=CC=[N+]([O-])C2=C1 YHQDZJICGQWFHK-UHFFFAOYSA-N 0.000 description 1
- BKGUPIVDQHHVMV-LSHKVNPSSA-N 64938-51-8 Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3[C@H](OC(=O)C(\C)=C\C)[C@@](C)(O)[C@@H](C)CC2=CC2=C1OCO2 BKGUPIVDQHHVMV-LSHKVNPSSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 244000058871 Echinochloa crus-galli Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010050208 Teratospermia Diseases 0.000 description 1
- 208000002312 Teratozoospermia Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007674 genetic toxicity Effects 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000005161 hepatic lobe Anatomy 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- STKUCSFEBXPTAY-GSUVRYNNSA-N methyl (4s,5z,6s)-5-ethylidene-4-[2-oxo-2-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[2-(4-hydroxyphenyl)ethoxy]oxan-2-yl]methoxy]ethyl]-6-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4h-pyran-3-carboxylate Chemical compound O([C@@H]\1OC=C([C@H](C/1=C/C)CC(=O)OC[C@@H]1[C@H]([C@H](O)[C@@H](O)[C@H](OCCC=2C=CC(O)=CC=2)O1)O)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O STKUCSFEBXPTAY-GSUVRYNNSA-N 0.000 description 1
- STKUCSFEBXPTAY-YTECAPLWSA-N methyl (5e,6s)-5-ethylidene-4-[2-oxo-2-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[2-(4-hydroxyphenyl)ethoxy]oxan-2-yl]methoxy]ethyl]-6-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4h-pyran-3-carboxylate Chemical compound O([C@@H]\1OC=C(C(C/1=C\C)CC(=O)OC[C@@H]1[C@H]([C@H](O)[C@@H](O)[C@H](OCCC=2C=CC(O)=CC=2)O1)O)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O STKUCSFEBXPTAY-YTECAPLWSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- STKUCSFEBXPTAY-KCWGXYKVSA-N nuezhenoside Natural products COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=CC)[C@@H]1CC(=O)OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O STKUCSFEBXPTAY-KCWGXYKVSA-N 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- FYSHYFPJBONYCQ-UHFFFAOYSA-N schisanhenol Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2O FYSHYFPJBONYCQ-UHFFFAOYSA-N 0.000 description 1
- BKGUPIVDQHHVMV-UHFFFAOYSA-N schisantherin C Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C(OC(=O)C(C)=CC)C(C)(O)C(C)CC2=CC2=C1OCO2 BKGUPIVDQHHVMV-UHFFFAOYSA-N 0.000 description 1
- 229930193195 schizandrin Natural products 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of Chinese medicine compositions for preventing hepatic injury, it is prepared using kudzu root extract, glossy privet fruit extract, raisin tree seed extract, Schisandra chinens P.E, Fructus lycii P.E, capejasmine extract as raw material, its weight proportion is 80 120 parts of kudzu root extract, 40 60 parts of glossy privet fruit extract, 40 60 parts of raisin tree seed extract, 24 36 parts of Schisandra chinens P.E, 24 36 parts of Fructus lycii P.E, 24 36 parts of capejasmine extract.
Description
Technical field
The present invention relates to pharmaceutical technology field, more particularly to a kind of Chinese medicine composition for being used to prevent hepatic injury.
Background technology
Liver diseases caused by hepatic injury have become a major issue in puzzlement global medical field.Hepatic injury includes
The types such as chemical damage, drug induced hepatic injury, immunological liver injury and alcoholic liver injury.One of the most common is alcohol
Property hepatic injury, alcoholic liver injury (ALD) is the liver diseases caused by long-term heavy drinking, and initial stage is usually expressed as fat
Liver, and then alcoholic hepatitis, alcoholic fibrosis and alcoholic cirrhosis can be developed into, seriously extensive liver can be induced during excessive drinking
Even meronecrosis liver failure.
The pathogenesis of ALD is not fully aware of at present, and the lipid peroxidation of free radical and its mediation is considered most main
The pathogenic factor wanted.Ethyl alcohol can generate a large amount of free radicals in liver metabolism：O2-, H2O2, OH-, C2H5O- and C2H5OH-, mistake
The free radical of amount can cause liver plasma membrane that peroxidatic reaction of lipid occurs, and destroy cell membrane and organelle structure, membrane fluidity
It is not normal；Enzyme (ALT, AST) is released into blood in a large amount of liver cells, and can exhaust removing free radical enzyme (SOD, GPx), liver cell damage
Wound further aggravates, dysfunction of liver, fat metabolic disturbance, ultimately results in liver cell extensive necrosis, and cellular swelling is dead.Cause
This, removes free radical anti-lipid peroxidation and reacts, protect liver cell, recover liver normal function, is that prevention ALD occurs and sends out
The key of exhibition.So far clinically there are no the ideal medicament of effective prevention alcoholic liver injury, therefore there is an urgent need for have safely in the market
Effect, the specific resisting alcoholic liver injury medicament of mechanism of action.
The content of the invention
The technical problems to be solved by the invention are to overcome the defect of the prior art, provide a kind of Chinese medicine for treating hepatic injury
Composition.
The present invention is stagnated with relieving alcoholism, clearing away damp-heat, soothing the liver courage, row, resolving sputum knot, by enhancing liver detoxification and enzymolysis, with
The decomposition and excretion of ethyl alcohol in diuresis acceleration bodies prevent alimentary canal to the absorption of ethyl alcohol and the effect of central nervous system,
Damage of the ethyl alcohol to liver is reduced, stimulated hepatic cell regeneration increases brain and coronal vascular flow, carrys out group for the purpose of alleviation poisoning symptom
Side.
Pueraria lobata, which is used to relieve the effect of alcohol, long-term clinical accumulation, golden ZHANG Cong-zheng《Confucian's Duties to Their Parents》In i.e. recorded recipe of relieving the effect of alcohol
" pueraria lobata dissipates ".Modern pharmacological studies have shown that it has an impact the absorption and metabolism of alcohol, it can be via anti-oxidant, liver protection, protection
The approach such as central nervous system play antialcoholism action.
Liver-protecting activity ingredient there are many containing in the fruit of glossy privet：Triterpenes components such as oleanolic acid, acetyloleanolic acid, ursolic acid
Deng；Iridoid such as Ligustrum lucidum Ait, Specnuezhenide, 10- hydroxyls Ligustrum lucidum Ait, new nuzhenide etc.；Benzyl carbinol-glycoside
Close object such as p-hydroxyphenylethanol-β-D glucosides (rhodioside)；Fructus Ligustri Lucidi polysaccharide etc..These active principles are by removing oxygen
Free radical and anti-hepatic fibrosis protect liver.
Hoveniae semoveniae semen has the effect of reducing fever and causing diuresis, relieving alcoholism, cures mainly the diseases such as wine poison, dysphoria with smothery sensation, thirsty, vomiting, difficulty in urination and defecation.The people
Between be known as the saying of " thousand glasss of not liquor-saturated hoveniae semoveniae semens ", ancient medical book《Hospital examines》In it is also on the books " hoveniae semoveniae semen (cockspur), relieves the effect of alcohol,
Excessively flower of kudzuvine.Hoveniae semoveniae semen can accelerating alcohol metabolism, reduce blood alcohol concentration after drinking, enhancing L-AD activity reduces liver
Dirty lipid peroxidation risk, hepatic injury caused by reducing ethyl alcohol etc..
Schisandra chinensis contains the lignan components such as schizandrin, Schisantherin C, schizandrin A and deoxyschizandrin,
These ingredients are the main matter bases of its hepatoprotective effect, and having improves liver function, mitigates liver cell lipid peroxidation injury, from
And prevent the effect of liver fibrosis.Wherein deoxyschizandrin can mitigate H2O2Caused human liver cell oxidative damage.
The fruit of Chinese wolfberry, name come from《Sheng Nong's herbal classic》, it is sweet in flavor, mild-natured, available for treatment because of kidney deficiency and liver, lung deficiency of the kidney void institute
Cause all diseases.Its polysaccharides has good protective effect for liver.
It is cape jasmine bitter, cold in nature, there is apocatharsis to be tired of, clearing heat and promoting diuresis, removing pattogenic heat from the blood and toxic material from the body the effect of, be clinically used hepatic cholagogic
Medicine.
Technical scheme is as follows：
A kind of Chinese medicine composition for preventing hepatic injury, with kudzu root extract, glossy privet fruit extract, raisin tree seed extract, five
Taste seed extract, Fructus lycii P.E, capejasmine extract are prepared for raw material, and weight proportion is kudzu root extract 80-120
Part, 40-60 parts of glossy privet fruit extract, 40-60 parts of raisin tree seed extract, 24-36 parts of Schisandra chinens P.E, Fructus lycii P.E
24-36 parts, 24-36 parts of capejasmine extract；Further preferably 100 parts of kudzu root extract, 50 parts of glossy privet fruit extract, hoveniae semoveniae semen
50 parts of extract, 30 parts of Schisandra chinens P.E, 30 parts of Fructus lycii P.E, 30 parts of capejasmine extract.
Kudzu root extract：Take pueraria lobata, add water to cook twice, collecting decoction, filter, filtrate concentration, it is dry to get.
Glossy privet fruit extract：Take the fruit of glossy privet, add water to cook twice, collecting decoction, filter, filtrate concentration, it is dry to get.
Raisin tree seed extract：Take hoveniae semoveniae semen, add water to cook twice, collecting decoction, filter, filtrate concentration, it is dry to get.
Schisandra chinens P.E：Schisandra chinensis is taken, adds 75~85% ethyl alcohol heating and refluxing extractions twice, merges extracting solution, is filtered,
Concentration, it is dry to get.
Fructus lycii P.E：Take the fruit of Chinese wolfberry, add water to cook twice, collecting decoction, filter, filtrate concentration, it is dry to get.
Capejasmine extract：Take cape jasmine, add water to cook twice, collecting decoction, filter, filtrate concentration, it is dry to get.
Present invention additionally comprises solid pharmaceutical preparation made of suitable pharmaceutic adjuvant is added with above-mentioned Chinese medicine composition, dosage form is piece
Agent, capsule or granule.
Present invention additionally comprises above-mentioned Chinese medicine compositions and its preparation to prepare the application in preventing liver injury medicament.
Above-mentioned Chinese medicine composition is after continuous 30 days oral gavages give female sd inbred rats, it is seen that animal growth is just
Often.On the basis of the establishment of alcoholic liver injury model, middle and high dosage group can significantly reduce the lipid peroxidation in rat liver homogenate
Matter catabolite mda content (P ＜ 0.01, P ＜ 0.05)；Reduced glutathione in middle and high dosage group rat liver homogenate
Content rise has significant difference (P ＜ 0.05, P ＜ 0.01)；Each dosage group content of triglyceride nothing compared with model control group
Significant difference (P ＞ 0.05).The fat stains scoring of middle and high dosage group, which reduces, significant difference (P ＜ 0.01, P ＜ 0.01),
Histopathological examination result is the positive.Above-mentioned composition has female sd inbred rats the auxiliary protection work(of alcoholic liver injury
Energy.
Specific embodiment
Protective effect of the embodiment 1 to alcoholic liver injury
1. experimental method
1.1 sample：The extract in table is removed, is uniformly mixed, it is spare.It is tested with distillation water as solvent preparation during experiment
Object, it is stored refrigerated.
| Formula | Formulation weight (Kg) |
| Kudzu root extract | 10 |
| Glossy privet fruit extract | 5 |
| Raisin tree seed extract | 5 |
| Schisandra chinens P.E | 3 |
| Capejasmine extract | 3 |
| Fructus lycii P.E | 3 |
The preparation method of each extract is as follows：
Kudzu root extract：Take pueraria lobata, the water of 8 times of weight added to decoct twice, every time 1.5 it is small when, collecting decoction filters, filter
Liquid concentrates, it is dry to get.
Glossy privet fruit extract：Take the fruit of glossy privet, the water of 8 times of weight added to decoct twice, every time 1.5 it is small when, collecting decoction, filter
Cross, filtrate concentration, it is dry to get.
Raisin tree seed extract：Take hoveniae semoveniae semen, the water of 8 times of weight added to decoct twice, every time 1.5 it is small when, collecting decoction, filter
Cross, filtrate concentration, it is dry to get.
Schisandra chinens P.E：Take Schisandra chinensis, add 8 times of 80% ethyl alcohol heating and refluxing extractions of weight twice, every time 1.5 it is small when,
Merge extracting solution, filter, concentration, it is dry to get.
Fructus lycii P.E：Take the fruit of Chinese wolfberry, the water of 8 times of weight added to decoct twice, every time 1.5 it is small when, collecting decoction, filter
Cross, filtrate concentration, it is dry to get.
Capejasmine extract：Take cape jasmine, the water of 8 times of weight added to decoct twice, every time 1.5 it is small when, collecting decoction filters, filter
Liquid concentrates, it is dry to get.
1.2 experimental animal：The female sd inbred rats 50 provided by Sichuan Provincial Academy of Traditional Chinese Medicine Experimental Animal Center, weight
181-220g, production licence number are 2013-19.SPF grades of SCXK (river).Animal feed is by Sichuan Academy of Medical Sciences Sichuan
Institute of lab animals of the People's Hospital of province provides, production licence number：SCXK (river) 2015-01.Experimental animal room uses license
Card number is SYXK (river) 2016-043. barrier systems, and temperature is 20-25 DEG C, relative humidity 40-70%.
1.3 dosage select and tested material gives mode：Female sd inbred rats are randomly divided into five groups, every group 10, experiment is set
Tri- dosage groups of 267mg/kg.BW, 800mg/kg.BW, 1600mg/kg.BW (be respectively equivalent to the daily recommended amounts of human body 5,
15th, 30 times), 6.68g, 20.00g, 40.00g tested material are weighed respectively, and successively plus distilled water is spare to 250ml mixings, is finished again
Match somebody with somebody.Separately set distilled water control group and 50% ethanol model control group.Liver injury model, concentration of alcohol are caused with ethyl alcohol (analysis is pure)
For 50% (being diluted with distilled water), gavage amount 14ml/kg.BW (dosage of equivalent ethyl alcohol is 7000mg/kg.BW).By 10ml/
Kg.BW daily once, continuously give 30 days, claim weight twice weekly, dosage is adjusted with this by oral gavage.1.4 test method：
Using alcoholic liver injury modelling, three dosage groups give the tested material of various dose, negative control group and model control group
Give distilled water.By model control group and three dosage groups, once oral gavage gives 50% ethanol solution, agent during off-test
It measures as 14ml/kg.BW, negative control group gives the distilled water of same volume, and putting to death animal after fasting 16h takes liver to weigh, and calculates
Dirty body ratio, and carry out biochemical indicator detection and histopathological examination with liver.
2. Testing index
Lipid peroxide catabolite malonaldehyde (MDA), reduced glutathione (GSH) and glycerine three in 2.1 liver homogenates
The measure of ester (TG)：MDA and GSH assay kits are built up Bioengineering Research Institute by Nanjing and are provided, with the U.S. science instrument in Shanghai day
The UV1100 spectrophotometric determinations of device Co., Ltd production；TG assay kits are diagnosed limited by German Olympus (Europe)
Company provides, and the AU-400 automatic clinical chemistry analyzers produced with Japanese Olympus Optical Co., Ltd are measured.
2.2 livers are weighed and the calculating of organ coefficient
2.3 pathology of hepar diagnostic criteria
2.3.1 pathological observation material：Cross section materials, section, dyeing, Microscopic observation fat drips are done in the middle part of from animal left lobe of liver
Distribution, scope and area in liver.
2.3.2 pathological observation method：Histotomy is observed continuously with 40 times of object lens in every animal liver tissue, according to positive thin
The how many scopes with distribution of born of the same parents, score by 0,1,2,3,4 point.Using the average value of obatained score as the fat of this hepatic tissue
Fat dyeing scoring.
2.3.3 pathological diagnosis standard：Pathologic examination is dyed using liver cell fat drips as observation index, and according to disease
Change degree " 0 ", " 1 ", " 2 ", " 3 ", " 4 " quantization are managed, carries out the evaluation of hepatic injury degree.
2.3.4 liver cell fat stains is divided into Pyatyi：
2.4 test datas count：Test data statistics is handled using SPSS11.0for windows software packages.Control group
For data with each dosage group through homogeneity test of variance, variance is neat, carries out variance analysis, if P values are less than 0.05, then uses Dunnett
Method is compared two-by-two；If heterogeneity of variance, data conversion is carried out, it is still uneven, use rank sum test instead, if P values are less than 0.05, then
With Dunnett, s T3 methods are compared two-by-two.Negative control group is then examined with model control group data using T.
2.5 result judgement：Liver MDA, tri- Testing index results positives of reduced form GSH and TG or liver MDA, reduced form
Wantonly two indexs are positive in tri- indexs of GSH and TG and histopathologic examination's result is positive.Meet any of the above condition, can sentence
The fixed given the test agent has and has auxiliary protection function to alcoholic liver injury.
3. result of the test
3.1 pairs of rat body weights, liver weight, liver body than influence
By table 1 as it can be seen that the original body mass of each dosage group rat is compared with negative control group and model control group, the neat (P of variance
＞ 0.05), the results of analysis of variance (P ＞ 0.05) illustrates that each group animal original body mass is balanced.The mid-term body of model control group
Weight, eventually weight, liver weight, liver body ratio are compared with negative control group, except liver weight, liver body than significantly rise (P ＜ 0.01, P ＜ 0.01) outside,
There was no significant difference for remaining index (P ＞ 0.05).The mid-term weight of each dosage group animal, eventually weight, liver weight and liver body ratio and model
Control group compares, and there was no significant difference (P ＞ 0.05).
Table 1 to rat body weight, liver weight, liver body than influence
Note：Δ Δ represents the P ＜ 0.01 compared with negative control group.
The influence of MDA, GSH, TG content in 3.2 pairs of rat liver homogenates
By table 2 as it can be seen that MDA, GSH, TG content in model control group rat liver homogenate are compared with negative control group, through t
It examines, MDA, TG content significantly raise (P ＜ 0.01, P ＜ 0.01), and GSH contents significantly reduce (P ＜ 0.01), show the model
It is successful, experimental system is reliable.MDA, GSH, TG content of three dosage groups are compared with model control group, it is seen that middle and high dose
The MDA of amount group is significantly reduced (P ＜ 0.01, P ＜ 0.05), and the GSH of middle and high dosage group significantly raises (P ＜ 0.05, P ＜ 0.01),
Each dosage group TG is without significant difference (P ＞ 0.05).
Influence of the table 2 to MDA, GSH, TG content in rat liver homogenate
Note：Δ Δ represents the P ＜ 0.01 compared with negative control group；* the P ＜ 0.05 compared with model control group are represented；* tables
Show the P ＜ 0.01 compared with model control group.
3.3 pathology of hepar inspection results
3 are the results are shown in Table, compared with negative control group, rise has pole for the liver cell fat stains scoring of model control group rat
Significant difference (P ＜ 0.01), it is successful to show the model, and experimental system is reliable.The liver cell fat of three dosage group rats
Compared with model control group, middle and high dosage group reduction has significant difference (P ＜ 0.01, P ＜ 0.01) for fat dyeing scoring.
Table 3 is to rat liver tissue pathological examination result
Note：Δ Δ represents the P ＜ 0.01 compared with negative control group；* represents the P ＜ 0.01 compared with model control group.
4. brief summary：
After oral gavage gives female sd inbred rats within continuous 30 days, it is seen that animal growth is normal.In alcoholic liver injury
On the basis of model is set up, middle and high dosage group can significantly reduce the lipid peroxide catabolite malonaldehyde in rat liver homogenate
Content (P ＜ 0.01, P ＜ 0.05)；Reduced glutathione content rise in middle and high dosage group rat liver homogenate has conspicuousness
Difference (P ＜ 0.05, P ＜ 0.01)；Each dosage group content of triglyceride is compared with model control group without significant difference (P ＞
0.05).The fat stains scoring of middle and high dosage group, which reduces, significant difference (P ＜ 0.01, P ＜ 0.01), histopathology inspection
The fruit that comes to an end is the positive.I.e. said composition has female sd inbred rats the assistant protection function of alcoholic liver injury.
2 safety evaluatio of embodiment is tested
1. experimental method
1.1 sample：1 sample of embodiment.Tested material is prepared with distillation water as solvent during experiment, it is stored refrigerated.
1.2 experimental animal：
1.2.1 feeding environment and feed resource：Experimental animal room is SYXK (river) 2011-043. barriers using credit number
System, 20-25 DEG C of temperature, relative humidity 40%-70%.Feed resource is in People's Hospital, Sichuan Prov. of Sichuan Academy of Medical Sciences
Institute of lab animals, production licence number are SCXK (river) 2015-01.
1.2.2 animal：Correlation test animal service condition is shown in Table 4.
4 experimental animal list of table
1.3 dosage select to give mode with tested material：
1.3.1 acute oral toxicity test：If mono- dosage group of 15000mg/kg.BW, by the oral gavages of 20ml/kg.BW.
Animal fasting 16h before gavage, unlimited drinking-water are observed 7 days after contaminating for the first time.
1.3.2Ames experiment：If the 8th, 40,200,1000,5,000 five dosage groups of μ g/ wares and solvent control group (distillation
Water), spontaneous control group and positive controls.
1.3.3 Micronucleus test：If 2000mg/kg.BW, 4000mg/kg.BW, 8000mg/kg.BW are (once most
Big gavage amount) three dosage groups, separately set solvent (distilled water) control and cyclophosphamide positive controls (CP, 40mg/kg.BW).
By the oral gavages of 20ml/kg.BW, two minor ticks for 24 hours, 30h are observed after contaminating for the first time.
1.3.4 sperm malformation test：If 2000mg/kg.BW, 4000mg/kg.BW, 8000mg/kg.BW are (once maximum to fill
Stomach amount) three dosage groups, separately set solvent (distilled water) control group and cyclophosphamide positive controls (CP, 40mg/kg.BW).Often
It is pressed
The oral gavages of 20ml/kg.BW continuous 5 days, are observed 35 days after contaminating for the first time.
1.3.5 30 days feeding trials：If tri- dosage groups of 1333mg/kg.BW, 2667mg/kg.BW, 5333mg/kg.BW
(25,50,100 times that are respectively equivalent to human body recommended intake), separately set full-valence pellet feed control group.It is first using mixing feeding
It is observed 30 days after secondary contamination.
1.4 main agents：Biochemical reagents box, cyclophosphamide, 1,8- dihydroxy anthraquinones, sodium azide, 2- aminofluorenes, 4- nitre
Base quinoline-N oxides, mitomycin C, S-9 mixed liquors.
1.5 test method：
1.5.1 acute oral toxicity test：Using maximum tolerated dose method, large and small mouse is randomly divided into two groups respectively, and totally 4
Group, 10 animals of every group of homology same sex.Weigh 75g tested materials add it is spare after distilled water to 200ml mixings.Large and small mouse is secondary to be given
Tested material is given, is spaced 4h.The poisoning manifestations and death condition of animal in one week are observed, off-test is put to death animal after weighing and made
Gross anatomy.
1.5.2 Salmonella reversion test：Using through β-naphthoflavene and phenobarbital combined induction male rat liver S9, by standard side
S is made in method9As activation system after mixed liquor, with indirect mutagen, (20 μ g/ ware 2- aminofluorenes are used for TA97、TA98、TA100,
50 μ g/ wares 1,8- dihydroxy anthraquinones are used for TA102Bacterium) measure S9Activity.Experiment is using TA97、TA98、TA100、TA102Four kinds of bacterial strains,
Tested material sets 8,40,200,1000,5,000 five dosage groups of μ g/ wares and solvent control group (distilled water), spontaneous control group and sun
Property control group.Tested material working solution is prepared first：5.0g samples accurately are weighed, it is most senior engineer to add distilled water to 100ml mixings
Make concentration 50mg/ml, it is highest tested material final concentration (5000 μ g/ wares) that when experiment, which takes 100 μ l of the working solution to add in plate, with
It is diluted down again up to following concentration with distilled water 5 based on maximum concentration.0.103MPa20min high pressure steam sterilizations.Adding
Be not added with S9Experimental condition under carry out tablet incorporation methods experiment.Three parallel wares of every group of work repeat experiment once.-S9It is positive right
According to object：TA97And TA98With the 4- nitroquinoline-N- oxides of 0.5 μ g/ wares；TA100With the sodium azide (NaN of 1.5 μ g/ wares3)；
TA102With the mitomycin C (MMC) of 1.0 μ g/ wares；+S9Positive control TA102With 1, the 8- dihydroxy anthraquinones of 50 μ g/ wares,
Excess-three bacterial strain uses the 2- aminofluorenes (2-AF) of 20 μ g/ wares.The volume that positive control is added in per ware is 0.1ml.
1.5.3 Micronucleus test：Using 30h dose regimens twice, mouse is randomly divided into 5 groups by male and female respectively,
Every group of 5 animals weigh 2.0g, 4.0g, 8.0g sample and distilled water are added separately to weigh 0.04gCP to 20ml and add distilled water extremely respectively
20ml, mixing, twice gavage interval for 24 hours, animal is put to death to 6h cervical dislocations after tested material in second, take breastbone marrow by
《Health food is examined and assessment technique specification》Regulation in (version in 2003) carries out film-making, fixed, after Giemsa dyeing, in oil
Every mouse counts the PCE numbers containing micronucleus in 1000 polychromatic erythrocytes (PCE) under mirror, calculates micronucleus cell rate (‰).It sees
Examine the ratio of polychromatic erythrocyte and mature erythrocyte (PCE/NCE) in 200 red blood cells.
1.5.4 sperm malformation test：Mouse is randomly divided into 5 groups, every group of 5 animals weigh 8.0g, 16.0g, 32.0g
Sample adds distilled water to 80ml respectively, separately weighs 0.04g CP and adds distilled water to 20ml (cyclophosphamide faces the used time and prepares daily),
Mixing.Continuous gavage 5 days, the 35th day after tested material is given for the first time, cervical dislocation puts to death animal and bilateral epididymal is taken to carry out film-making,
It presses《Health food is examined and assessment technique specification》Regulation in (version in 2003), methanol is fixed, after 1% eosin stains, in height
Every animal counts 1000 complete sperms under times mirror, record teratospermia, lopsided type and calculates rate of teratosperm.
1.5.530 day feeding trial：Using mixing feeding, rat is randomly divided into 4 groups, every group of 20 rats, half male and half female.
Each 14kg of feed containing tested material is prepared, about 187g, 373g, 747g tested material is weighed respectively, is first added sequentially to 3kg feeds
In, because high dose group tested material content is more than 5%, protein is supplemented with 186g casein, after being sufficiently stirred mixing, by remaining feeding
Material is added thereto to total amount 14Kg, then after being sufficiently stirred mixing, machine-shaping is spare after Co 60 irradiation.Daily every rat list
Cage is fed, continuous 30 days, is observed general performance, behavior, poisoning manifestations and the death of animal daily, is calculated feed twice weekly
Amount, and claim a weight according to food intake dose, calculates food utilization, and that blood is taken to put to death is dynamic for anesthesia after fasting during off-test
Object, blood sampling measures hematological indices with XT-2000i types Automatic Blood Cell Analyzer, with Japanese Olympus optics strain formula meeting
The AU-400 automatic clinical chemistry analyzers of society's production and German Olympus (Europe) diagnose the kit that Co., Ltd provides, and survey
Determine blood biochemistry index, dissection animal observation internal organ change, and claim liver,kidney,spleen, testis weight, calculate its dirty body ratio, take liver,kidney,spleen,
Stomach and intestine, testis (ovary) make histopathological examination.Animal ad lib, drinking-water during experiment.
1.6 test datas count：Bone marrow micronucleus test use Chi-square Test, sperm malformation test use rank sum test, 30
For its feeding trial data through homogeneity test of variance, variance is neat, carries out variance analysis, if P values are less than 0.05 with Dunnett methods into
Row compares two-by-two；If heterogeneity of variance, data conversion is carried out, it is still uneven, it uses rank sum test instead, if P values are less than 0.05, then uses
Dunnett ' s T3 methods are compared two-by-two, and above-mentioned statistics uses 11.0 for Windows software processings of SPSS.
1.7 result judgement：
1.7.1 acute oral toxicity test：According to LD50Numerical value judges the toxicity grading of tested material.
1.7.2 Salmonella reversion test：Tested material group time change clump count (returns more than doubling and becomes clump count equal to or more than 2
Be multiplied by untreated control number), and have a dose-response relationship or at least a certain test point have it is repeatable and statistically significant
Positive reaction, you can think the tested material mutagenesis testing positive.
1.7.3 Micronucleus test：Compared with the control group, result of the test micronuclear rates has the apparent dosage anti-to test group
Should be related to and it is statistically significant when, you can confirm as positive findings.If statistically difference has conspicuousness, but without dose response
During relation, then it must carry out repeating experiment.As a result can the person of repetition can be identified as the positive.
1.7.4 sperm malformation test：Each dosage group should be respectively compared with corresponding negative control group, and abnormal rate is extremely
Less for times amount of negative control group or through counting significance, and there is dose-response relationship, you can be determined as the positive.
2. experimental result
2.1 couples of large and small equal ＞ 15000mg/kg.BW of mouse acute oral toxicity test result MTD values, by acute toxicity point
Grade, belongs to nontoxic grade.
2.2 3 genetic toxicity tests (Salmonella reversion test, mice bone marrow micronucleus and mouse sperms
Deformity experiment) result has no mutagenesis.
2.3 30 days feeding trials, it is seen that animal growth is normal, and continued weight increases, and figure is active, and hair is smooth
Submissive, stool, urine no abnormality seen changes.Have no that poisoning symptom and death occurs in animal during experiment.Three dosage groups are female great and mighty or powerful
The weight weekly of mouse, weekly food-intake, weekly food utilization, total food utilization rate, dirty body ratio, hematological indices and latter stage
Compared with the control group, the 4th week food-intake of high dose group significantly reduces (P ＜ 0.05), high dose group to Biochemistry test result
Glutamic-pyruvic transaminase significantly reduce (P ＜ 0.05), low middle high dose group T-CHOL significantly reduces (P ＜ 0.01, P ＜ 0.01, P
＜ 0.01), male mouse is low, the lymphocyte of the leucocyte of high dose group and high dose group significantly reduces (P ＜ 0.05, P ＜ 0.05, P
＜ 0.01), neutrality significantly rise (P ＜ 0.05), the high dose group albumin of high dose group significantly raise (P ＜ 0.01), middle dose
Amount group urine glutamic-oxalacetic transaminease significantly reduces (P ＜ 0.05).More than institute measured value is in this room range of normal value.Histopathology is examined
It looks into as a result, in addition to the spontaneous lesion of animal, has no that tested material high dose group causes animal poisoning damage to change.
3 capsule of embodiment
| Supplementary material title | Formula ratio (g) |
| Kudzu root extract | 100 |
| Glossy privet fruit extract | 50 |
| Raisin tree seed extract | 50 |
| Schisandra chinens P.E | 30 |
| Capejasmine extract | 30 |
| Fructus lycii P.E | 30 |
| Magnesium stearate | 2 |
| It is made | 1000 |
Preparation method：Above-mentioned 6 kinds of extracts are taken, are uniformly mixed, dry method pelleting adds in magnesium stearate, is uniformly mixed, dress
Enter capsule to get.
4 granule of embodiment
| Supplementary material title | Formula ratio (g) |
| Kudzu root extract | 1000 |
| Glossy privet fruit extract | 500 |
| Raisin tree seed extract | 500 |
| Schisandra chinens P.E | 300 |
| Capejasmine extract | 300 |
| Fructus lycii P.E | 300 |
| Maltodextrin | 3600g |
| Mannitol | 1500g |
| It is made | 1000 bags |
Preparation method：By maltodextrin, mannitol, kudzu root extract, glossy privet fruit extract, raisin tree seed extract, five
Taste seed extract, capejasmine extract, wolfberry fruit extract add in wet granulator, using 85% ethanol solution as wetting agent preparation
Grain, whole grain after particle drying, pack to get.
The preferred embodiment of the present invention has been described above in detail, still, during present invention is not limited to the embodiments described above
Detail, within the scope of the technical concept of the present invention, a variety of simple variants can be carried out to technical scheme, this
A little simple variants all belong to the scope of protection of the present invention.
It is further to note that the specific technical features described in the above specific embodiments, in not lance
In the case of shield, can be combined by any suitable means, in order to avoid unnecessary repetition, the present invention to it is various can
The combination of energy no longer separately illustrates.
In addition, various embodiments of the present invention can be combined randomly, as long as it is without prejudice to originally
The thought of invention, it should also be regarded as the disclosure of the present invention.
Claims (5)
1. a kind of Chinese medicine composition for preventing hepatic injury, with kudzu root extract, glossy privet fruit extract, raisin tree seed extract, the five tastes
Seed extract, Fructus lycii P.E, capejasmine extract are prepared for raw material, and weight proportion is kudzu root extract 80-120
Part, 40-60 parts of glossy privet fruit extract, 40-60 parts of raisin tree seed extract, 24-36 parts of Schisandra chinens P.E, Fructus lycii P.E
24-36 parts, 24-36 parts of capejasmine extract.
2. Chinese medicine composition according to claim 1, which is characterized in that its weight proportion be 100 parts of kudzu root extract, female
Loyal 50 parts of seed extract, 50 parts of raisin tree seed extract, 30 parts of Schisandra chinens P.E, 30 parts of Fructus lycii P.E, capejasmine extract
30 parts.
3. solid pharmaceutical preparation made of Chinese medicine composition according to claim 1 or 2, dosage form is tablet, capsule or granule.
4. according to any Chinese medicine compositions of claim 1-3, which is characterized in that the kudzu root extract preparation method
For：Take pueraria lobata, add water to cook twice, collecting decoction, filter, filtrate concentration, it is dry to get；
The glossy privet fruit extract preparation method is：The fruit of glossy privet is taken, is added water to cook twice, collecting decoction, is filtered, filtrate is dense
Contracting, it is dry to get；
The raisin tree seed extract preparation method is to take hoveniae semoveniae semen, is added water to cook twice, collecting decoction, is filtered, filtrate concentration,
It is dry to get；
The Schisandra chinens P.E preparation method adds 75~85% ethyl alcohol heating and refluxing extractions twice, merges to take Schisandra chinensis
Extracting solution filters, concentration, it is dry to get；
The Fructus lycii P.E preparation method is to take the fruit of Chinese wolfberry, is added water to cook twice, collecting decoction, is filtered, filtrate concentration,
It is dry to get；
The preparation method of the capejasmine extract is added water to cook twice, collecting decoction, filtered, filtrate concentration is done to take cape jasmine
It is dry to get.
5. any Chinese medicine compositions of claim 1-4 are preparing the application in preventing liver injury medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711347613.2A CN108114083A (en) | 2017-12-05 | 2017-12-05 | A kind of Chinese medicine composition for preventing hepatic injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711347613.2A CN108114083A (en) | 2017-12-05 | 2017-12-05 | A kind of Chinese medicine composition for preventing hepatic injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108114083A true CN108114083A (en) | 2018-06-05 |
Family
ID=62230196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711347613.2A Pending CN108114083A (en) | 2017-12-05 | 2017-12-05 | A kind of Chinese medicine composition for preventing hepatic injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108114083A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114027503A (en) * | 2021-11-29 | 2022-02-11 | 乐泰药业有限公司 | Composition with auxiliary protection function on chemical liver injury and quality evaluation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1528429A (en) * | 2003-10-20 | 2004-09-15 | 上海澳博海洋生物技术开发有限公司 | Chinese medicine preparation with accessory protection action to alcoholic liver injury and preparing method thereof |
| CN101422523A (en) * | 2008-12-02 | 2009-05-06 | 昆明振华制药厂有限公司 | Health-care preparation capable of alleviating a hangover and protecting the liver and preparation method thereof |
-
2017
- 2017-12-05 CN CN201711347613.2A patent/CN108114083A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1528429A (en) * | 2003-10-20 | 2004-09-15 | 上海澳博海洋生物技术开发有限公司 | Chinese medicine preparation with accessory protection action to alcoholic liver injury and preparing method thereof |
| CN101422523A (en) * | 2008-12-02 | 2009-05-06 | 昆明振华制药厂有限公司 | Health-care preparation capable of alleviating a hangover and protecting the liver and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 刘艳红: "女贞子不同炮制品对小鼠肝损伤的保护作用研究", 《黑龙江科技信息》 * |
| 姜忠晶等: "浅论五味子对肝脏的作用", 《黑龙江中医药》 * |
| 渔翁很快乐: "昂仕牌葛根栀子胶囊", 《HTTP://CACHE.BAIDUCONTENT.COM/C?M=9F65CB4A8C8507ED4FECE763105392230E54F76238D586482EC3933FC23846120720B8EA79750D05D4CF7D6D02B84E28EAFB3378300227B39BDF883D87FDCD763BCD7A742613913110C469DCDC4755D651E34D98DF0EE6CAE74394B9A3D7C85523DD230F6DF4F29C2A0A03B * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114027503A (en) * | 2021-11-29 | 2022-02-11 | 乐泰药业有限公司 | Composition with auxiliary protection function on chemical liver injury and quality evaluation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101095751B (en) | Medicinal composition having functions of removing chloasma and improving nutritional anemia and method for preparing the same | |
| CN101422523A (en) | Health-care preparation capable of alleviating a hangover and protecting the liver and preparation method thereof | |
| CN108576819A (en) | A kind of liver-protecting combination, health food, preparation method and applications | |
| CN102429949B (en) | Liver-protecting medicine or health care product composition and preparation method and application thereof | |
| CN101862351A (en) | Application of active parts of gallnut in preparing anti-ulcerative colitis medicine | |
| CN106214773B (en) | A kind of pair of chemical damage has composition of assistant protection function and preparation method thereof | |
| CN103784635A (en) | Intelligence-promoting capsule for improving memory and preparation method thereof | |
| Saiyed et al. | Safety and toxicological evaluation of Meratrim®: An herbal formulation for weight management | |
| CN101658597A (en) | Health care step-down tea and preparation method thereof | |
| CN102335394B (en) | Chinese medicinal composition for treating cervical erosion and preparation method thereof | |
| Li | Chinese herbal medicine | |
| CN108066473B (en) | Preparation with protective effect on chemical liver injury and preparation method thereof | |
| CN104383447B (en) | A kind of Traditional Chinese medicine composition and preparation method and application | |
| CN108114083A (en) | A kind of Chinese medicine composition for preventing hepatic injury | |
| CN103860706B (en) | A kind of pure Chinese medicine health preparation with protection alcoholic liver injury function | |
| CN110755322A (en) | Jindan anti-allergy traditional Chinese medicine extract and preparation method and application thereof | |
| CN110604712A (en) | Anti-inflammatory repair composition, preparation and preparation method thereof | |
| CN114191358B (en) | Plant composition with whitening effect and application of plant composition in cosmetics | |
| CN102266428B (en) | Anti-ageing Chinese medicinal composition and preparation method and application thereof | |
| Sulaimon et al. | Evaluation of antidiabetic activity of Irvingia gabonensis (Aubry-Lecomte ex O’Rorke) leaf and bark in alloxan induced diabetic rats | |
| CN103263458B (en) | Liver-protecting medicine or health-care product composition as well as preparation method and use thereof | |
| CN111821331A (en) | External gel for repelling mosquitoes, relieving itching and diminishing swelling and preparation method thereof | |
| CN108607044A (en) | A kind of strengthen immunity, the health products and its preparation process for improving chronic pharyngitis symptom | |
| CN114470050B (en) | A Chinese medicinal composition for resisting sensitization, relieving itching and/or repairing skin | |
| Gim et al. | Antioxidant effect of tianwang buxin pills a traditional Chinese medicine formula: double-blind, randomized controlled trial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180605 |